title: Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.
authors: KU Leuven, University of Leuven, Center for Human Genetics, Belgium.
authors: Julio Finalet
authors: JF
authors: Ferreiro
authors: KU Leuven, University of Leuven, Translational Cell and Tissue Research and KU Leuven, University Hospitals Leuven, Department of Pathology, Belgium.
authors: Julie
authors: J
authors: Morscio
authors: KU Leuven, University Hospitals Leuven, Department of Hematology, Belgium.
authors: Daan
authors: D
authors: Dierickx
authors: KU Leuven, University of Leuven, Translational Cell and Tissue Research and KU Leuven, University Hospitals Leuven, Department of Pathology, Belgium.
authors: Lukas
authors: L
authors: Marcelis
authors: KU Leuven, University Hospitals Leuven, Department of Hematology, Belgium.
authors: Gregor
authors: G
authors: Verhoef
authors: KU Leuven, University of Leuven, Center for Human Genetics, Belgium.
authors: Peter
authors: P
authors: Vandenberghe
authors: KU Leuven, University of Leuven, Translational Cell and Tissue Research and KU Leuven, University Hospitals Leuven, Department of Pathology, Belgium.
authors: Thomas
authors: T
authors: Tousseyn
authors: KU Leuven, University of Leuven, Center for Human Genetics, Belgium iwona.wlodarska@uzleuven.be.
authors: Iwona
authors: I
authors: Wlodarska
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000235:genetics / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000209:etiology / Q000235:genetics* / Q000401:mortality; D002880:Chromosomes, Human, Pair 11; D003520:Cyclophosphamide; D004317:Doxorubicin; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000209:etiology / Q000235:genetics* / Q000401:mortality; D015972:Gene Expression Regulation, Neoplastic; D053263:Gene Regulatory Networks; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D009154:Mutation; D011241:Prednisone; D050784:Proto-Oncogene Protein c-ets-1 / Q000235:genetics / Q000378:metabolism; D051789:Proto-Oncogene Protein c-fli-1 / Q000235:genetics / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D000069283:Rituximab / Q000627:therapeutic use; D015398:Signal Transduction; D016019:Survival Analysis; D014178:Translocation, Genetic; D014750:Vincristine
chemical_list: C494041:ETS1 protein, human; C078433:FLI1 protein, human; C489427:MYC protein, human; D008869:Microtubule-Associated Proteins; D050784:Proto-Oncogene Protein c-ets-1; D051789:Proto-Oncogene Protein c-fli-1; D016271:Proto-Oncogene Proteins c-myc; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C523923:PAFAH1B2 protein, human; D011241:Prednisone
keywords: 11q; Burkitt lymphoma; PTLD; post-transplant lymphoproliferative disease